Dr. Yan Wang 王燕
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized and individualized treatment of thoracic tumors, with a focus on precision therapy for lung cancer including chemotherapy, targeted therapy, and immunotherapy. Also experienced in chemotherapy and targeted therapy for breast, gastric, esophageal, and colorectal cancers.
Dr. Wang is a Chief Physician and doctoral supervisor at the Cancer Hospital, Chinese Academy of Medical Sciences. After graduating from Hunan Medical University in 1993, Dr. Wang pursued advanced training in the UK and US under Academician Sun Yan. The doctor has led multiple ministerial and institutional research projects and published over 60 academic papers.
Professional roles
- Editorial Board Member for multiple professional journals
Name order: in Chinese the family name comes first (Wang Yan). Papers usually list the name as Yan Wang or Wang Y.
Selected publications
332 papers on PubMed matched by name and affiliation; 61 as first or senior author since 2016. Most recent first- or senior-author papers:
- Acta Pharm Sin B, 2026 (first author): Post CDK4/6 inhibitors: Novel targeted combinations based on SERDs in HR(+)/HER2(-) advanced breast cancer. PubMed 42948694
- Exp Ther Med, 2026 (senior author): Integrating clinical outcomes with molecular simulations to guide the selection of non-classical EGFR-TKIs: A comprehensive analysis and development of treatment strategies. PubMed 42719457
- Lung Cancer, 2026 (senior author): First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial. PubMed 42691829
- Front Oncol, 2026 (senior author): Small cell transformation during acquired resistance to zongertinib in HER2-mutant non-small cell lung cancer: a case report. PubMed 42856622
- Curr Cancer Drug Targets, 2026 (senior author): Clinicopathological Profiles and Prognosis of Postoperative HER2-Mutant Non-Small Cell Lung Cancer: A Real-World Analysis. PubMed 42708295
- Respir Res, 2026 (senior author): Circulating tumor DNA dynamics and mutational profiles as indicators in neoadjuvant chemoimmunotherapy for resectable or borderline resectable non-small cell lung cancer. PubMed 43004398
- Clin Transl Oncol, 2026 (senior author): Adjuvant immunotherapy in resected non-small cell lung cancer harboring oncogenic driver alterations beyond EGFR and ALK: results from a retrospective analysis. PubMed 42503059
- Nurs Open, 2026 (first author): Decision-Making Readiness and Its Influencing Factors Among Lung Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study. PubMed 42366843
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion